Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22809757 | 0.89 | ALDH1A1 (0.44) | HSPB1ALDH1A1HTTERN1TRPA1 | |
| SCHEMBL19563735 | 0.86 | SCN8A (0.46) | HSPB1ALDH1A1HTTTRPA1EPAS1 | |
| SCHEMBL21129891 | 0.85 | HSPB1 (0.41) | HSPB1ALDH1A1HTTERN1TRPA1 | |
| SCHEMBL18570698 | 0.83 | SCN8A (0.47) | HSPB1ALDH1A1HTTTRPA1EPAS1 | |
| SCHEMBL19563641 | 0.82 | SLC6A4 (0.43) | ALDH1A1ERN1MAPT | |
| SCHEMBL10456772 | 0.82 | TRPA1 (0.56) | HSPB1ALDH1A1TRPA1EPAS1 | |
| SCHEMBL5276414 | 0.82 | HSPB1 (0.46) | HSPB1ALDH1A1HTTERN1TRPA1 | |
| SCHEMBL274702 | 0.81 | LMNA (0.52) | HSPB1ALDH1A1ERN1EPAS1KMT2A | |
| SCHEMBL19524123 | 0.80 | ERN1 (0.41) | HSPB1ALDH1A1HTTERN1TRPA1 | |
| SCHEMBL5991434 | 0.80 | SCN8A (0.45) | HSPB1ALDH1A1HTTERN1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134001-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-2229396-B1 | SPIROINDOLINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2011-08-10 | — | — | EP | disclosed |
| EP-2229396-A1 | SPIROINDOLINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009077357-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-20090156610-A1 | Spiroindolinone Derivatives | DING QINGJIE | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156610-A1 | Spiroindolinone Derivatives | SDHA, AR, XPOT | HSPB1 2684/4885ALDH1A1 138/4885HTT 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.